STOCK TITAN

PharmaCyte Biotech, Inc. - PMCB STOCK NEWS

Welcome to our dedicated page for PharmaCyte Biotech news (Ticker: PMCB), a resource for investors and traders seeking the latest updates and insights on PharmaCyte Biotech stock.

PharmaCyte Biotech, Inc. (PMCB) is a clinical-stage biotechnology company dedicated to the development and commercialization of innovative cellular therapies for cancer and diabetes. The company's core technology, known as Cell-in-a-Box, is a proprietary cellulose-based live cell encapsulation platform. This cutting-edge technology is designed to offer targeted and effective treatment options for various types of cancer, including advanced and non-metastatic pancreatic cancer, as well as insulin-dependent diabetes.

PharmaCyte's primary focus is on developing therapies for pancreatic and other solid cancerous tumors. The Cell-in-a-Box technology enables the encapsulation of live cells, which are placed within the body to deliver cancer-killing drugs directly to the tumor site. This approach ensures that the therapeutic agents are activated at the cancer source, minimizing damage to surrounding healthy tissues.

In addition to its cancer therapies, PharmaCyte is actively developing treatments for diabetes. The company is working on creating a therapy for type 1 diabetes and insulin-dependent type 2 diabetes by encapsulating Melligen cells, which are designed to produce insulin. To advance this research, PharmaCyte has entered into a research agreement with the University of Technology, Sydney. They are also exploring therapies for cancer based on the constituents of the cannabis plant, expanding the potential applications of their proprietary technology.

PharmaCyte Biotech’s innovative approach and strategic partnerships position it at the forefront of biotechnological advancements in cancer and diabetes treatment. With ongoing research and development, the company aims to transform the therapeutic landscape and provide new hope for patients facing these challenging diseases.

Rhea-AI Summary

PharmaCyte Biotech (NASDAQ: PMCB) announced positive results from a third test of its CypCaps product for pancreatic cancer, confirming that the capsule material is non-mutagenic. This aligns with their ongoing commitment to meet FDA data requirements and supports the safety of their product. The third-party study adheres to OECD standards and emphasizes the device's safety profile. The company continues to develop therapies for cancer and diabetes using their Cell-in-a-Box technology, positioning itself for future advancements in treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

PharmaCyte Biotech (NASDAQ: PMCB) announced positive results from its second FDA-required biocompatibility test of the CypCaps™ product, revealing that the capsule material is non-hemolytic. This test confirms earlier findings that the biocompatibility of the capsule does not cause blood cell destruction. Conducted by a third-party organization, the results align with PharmaCyte’s goal of developing cellular therapies for pancreatic cancer and diabetes using its Cell-in-a-Box® technology, enhancing prospects for clinical advancement.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.79%
Tags
none
-
Rhea-AI Summary

PharmaCyte Biotech (NASDAQ: PMCB) announced the initial results of biocompatibility studies for its CypCaps product, a component in its pancreatic cancer treatment. The study confirmed that the cellulose sulphate capsules do not activate the complement system, a key part of the human immune response, ensuring safety for patients. Conducted by a third-party GLP lab, this study is part of ongoing research to evaluate the CypCaps' effectiveness and compatibility. Further results from additional studies are expected in the coming weeks.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.79%
Tags
none
Rhea-AI Summary

PharmaCyte Biotech (NASDAQ: PMCB) announced its participation in the H.C. Wainwright 23rd Annual Global Investment Conference, taking place virtually from September 13-15, 2021. CEO Kenneth L. Waggoner will present and engage in meetings with institutional investors. He emphasized the company's milestone of having sufficient capital for ongoing development of its cancer and diabetes cellular therapies, which utilize the proprietary Cell-in-a-Box® technology. The presentation will be available on-demand from September 13, 2021, at 7:00 a.m. EDT.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.56%
Tags
conferences
-
Rhea-AI Summary

PharmaCyte Biotech (NASDAQ: PMCB) announced that its clinical trial product, CypCaps™, remains stable and active 18 months post-storage at -80ºC, affirming a minimum shelf life of 18 months. This positive stability data will contribute to PharmaCyte's updated submission to the FDA aimed at lifting the clinical hold on its Investigational New Drug application (IND) for the treatment of inoperable pancreatic cancer. The ongoing study confirms product integrity and viability, supporting the company’s goal to advance to a Phase 2b clinical trial.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.12%
Tags
-
Rhea-AI Summary

PharmaCyte Biotech (NASDAQ: PMCB) has announced an expansion of its product pipeline to include diabetes and malignant ascites programs, following the successful closing of two public offerings that raised approximately $90 million. CEO Kenneth L. Waggoner emphasized that this funding enables the company to lift the clinical hold imposed by the FDA and proceed with a clinical trial for locally advanced, inoperable pancreatic cancer (LAPC). The additional capital allows PharmaCyte to broaden its development efforts, having previously focused solely on LAPC.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.12%
Tags
none
Rhea-AI Summary

PharmaCyte Biotech (NASDAQ: PMCB) has entered into definitive agreements for a registered direct offering of 14 million shares at $5.00 per share, raising gross proceeds of $70 million. The offering includes unregistered warrants to purchase 7 million additional shares. The funds will be used to address the FDA's clinical hold and conduct a Phase 2b trial for pancreatic cancer. The offering is expected to close around August 23, 2021, pending customary conditions, with H.C. Wainwright & Co. as the placement agent.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-64.85%
Tags
-
Rhea-AI Summary

PharmaCyte Biotech (NASDAQ: PMCB) announced its successful listing on Nasdaq, marking a significant milestone aimed at enhancing shareholder value. CEO Kenneth L. Waggoner highlighted the benefits of the move, including improved liquidity, expanded shareholder base, and access to capital for advancing their cellular therapies targeting pancreatic cancer and diabetes. A recent $15 million public offering, facilitated by their reverse stock split, will support efforts to address FDA clinical hold requests and launch clinical trials. The company emphasizes increased visibility and opportunities through the Nasdaq platform.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.48%
Tags
none
-
Rhea-AI Summary

PharmaCyte Biotech (NASDAQ: PMCB) has successfully closed a public offering, raising approximately $15 million. The offering included 3,529,412 shares of common stock and warrants for the same number of shares, with net proceeds of about $13.6 million after deductions. The underwriter, H.C. Wainwright, received an option for an additional 529,411 shares and has partially exercised it. PharmaCyte focuses on developing therapies for cancer and diabetes using its Cell-in-a-Box technology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-20.28%
Tags
Rhea-AI Summary

PharmaCyte Biotech, Inc. (NASDAQ: PMCB) has announced the commencement of trading on The Nasdaq Capital Market starting August 10, 2021. The company priced an underwritten public offering of 3,529,412 shares at $4.25 each, yielding approximately $15 million in gross proceeds before expenses. This offering includes warrants exercisable for additional shares and a 30-day option for underwriters to purchase more shares. The offering aims to support PharmaCyte's development of innovative therapies for cancer and diabetes using its Cell-in-a-Box® technology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-56.71%
Tags

FAQ

What is the current stock price of PharmaCyte Biotech (PMCB)?

The current stock price of PharmaCyte Biotech (PMCB) is $1.75 as of November 21, 2024.

What is the market cap of PharmaCyte Biotech (PMCB)?

The market cap of PharmaCyte Biotech (PMCB) is approximately 12.9M.

What is PharmaCyte Biotech, Inc.?

PharmaCyte Biotech, Inc. is a clinical-stage biotechnology company focused on developing cellular therapies for cancer and diabetes.

What technology does PharmaCyte use for its therapies?

PharmaCyte uses a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box for its therapies.

What types of cancer is PharmaCyte targeting?

PharmaCyte is targeting various types of cancer, including advanced and non-metastatic pancreatic cancer, as well as other solid tumors.

What is the Cell-in-a-Box technology?

Cell-in-a-Box is a proprietary technology that encapsulates live cells for targeted delivery of cancer-killing drugs directly to tumor sites.

Is PharmaCyte developing therapies for diabetes?

Yes, PharmaCyte is developing therapies for type 1 diabetes and insulin-dependent type 2 diabetes by encapsulating Melligen cells.

Does PharmaCyte have any research partnerships?

PharmaCyte has a research agreement with the University of Technology, Sydney to develop Melligen cells for diabetes treatment.

What makes PharmaCyte's approach to cancer treatment unique?

PharmaCyte's approach is unique because it uses encapsulated live cells to deliver cancer-killing drugs directly to the tumor, reducing damage to healthy tissues.

Is PharmaCyte involved in cannabis-based therapies?

Yes, PharmaCyte is exploring therapies for cancer based on the constituents of the cannabis plant.

What stage is PharmaCyte Biotech currently in?

PharmaCyte Biotech is in the clinical stage, focused on advancing its therapies through research and development.

Where can I find the latest news about PharmaCyte Biotech?

You can find the latest news about PharmaCyte Biotech on stock market websites like StockTitan or the company's official website.

PharmaCyte Biotech, Inc.

Nasdaq:PMCB

PMCB Rankings

PMCB Stock Data

12.90M
6.23M
8.89%
13.16%
0.8%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
LAGUNA HILLS